Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
- PMID: 27430122
- PMCID: PMC5963200
- DOI: 10.1080/21505594.2016.1213476
Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
Abstract
The objective of this study was to assess the achievement of pharmacokinetic/pharmacodynamic (PK/PD) targets of meropenem (MEM) in critically-ill patients with bloodstream infections (BSI) due to Klebsiella pneumoniae-carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) with MEM minimum inhibitory concentrations (MICs) ≥16 mg/L. Nineteen critically-ill patients with KPC-Kp BSI were given combination therapy including MEM, tigecycline, plus colistin or gentamicin (according to susceptibility testing). MEM was administered as an extended 3-hour infusion of 2 g every 8 hours, or adjusted according to renal function. MEM plasma concentrations were determined by high-performance liquid chromatography. PK/PD targets for MEM were defined as T > 40% 1×MIC and T > 40% 4×MIC. Possible synergisms between MEM and coadministered agents were assessed by time-kill assays based on plasma levels for MEM and on fixed plasma concentrations for the other agents. In none of 19 patients MEM reached any PK/PD target. The actual MEM MICs were 256, 512, and 1024 mg/L in 1, 3, and 15 isolates, respectively. However, theoretically, the PK/PD target of T > 40% 1×MIC could have been achieved in 95%, 68%, 32% and 0% of the isolates for MIC equal to 8, 16, 32, and 64 mg/L, respectively. No synergisms were observed between MEM and coadministered agents. In conclusion, high-dose MEM failed to reach PK/PD targets in 19 patients with BSI due to KPC-Kp with very high MEM MICs. On a theoretical basis, our results suggest a possible usefulness of MEM against resistant blood isolates with MICs up to 32 mg/L.
Keywords: KPC; Klebsiella pneumoniae; PK/PD; bloodstream infections; carbapenemases; meropenem MICs; treatment.
Figures

Comment in
-
Using carbapenems for carbapenem-resistant Klebsiella pneumoniae-Are we flogging a dead (work)horse antibiotic?Virulence. 2017 Jan 2;8(1):13-14. doi: 10.1080/21505594.2016.1231756. Epub 2016 Sep 3. Virulence. 2017. PMID: 27593359 Free PMC article. No abstract available.
Similar articles
-
Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00794-17. doi: 10.1128/AAC.00794-17. Print 2017 Oct. Antimicrob Agents Chemother. 2017. PMID: 28760900 Free PMC article.
-
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?Int J Antimicrob Agents. 2017 Feb;49(2):255-258. doi: 10.1016/j.ijantimicag.2016.10.018. Epub 2016 Dec 8. Int J Antimicrob Agents. 2017. PMID: 28012683
-
Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00406-17. doi: 10.1128/AAC.00406-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28559247 Free PMC article.
-
Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda.Future Microbiol. 2015;10(2):283-94. doi: 10.2217/fmb.14.121. Future Microbiol. 2015. PMID: 25689539 Review.
-
Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.J Antimicrob Chemother. 2010 Jun;65(6):1119-25. doi: 10.1093/jac/dkq108. Epub 2010 Apr 8. J Antimicrob Chemother. 2010. PMID: 20378670 Review.
Cited by
-
Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation.Front Microbiol. 2019 Nov 29;10:2777. doi: 10.3389/fmicb.2019.02777. eCollection 2019. Front Microbiol. 2019. PMID: 31849910 Free PMC article.
-
Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades.Ann Med. 2023 Dec;55(1):101-113. doi: 10.1080/07853890.2022.2152484. Ann Med. 2023. PMID: 36856521 Free PMC article.
-
Carbapenem-Resistant Klebsiella pneumoniae: Microbiology Key Points for Clinical Practice.Int J Gen Med. 2019 Nov 28;12:437-446. doi: 10.2147/IJGM.S214305. eCollection 2019. Int J Gen Med. 2019. PMID: 31819594 Free PMC article. Review.
-
Outcome of carbapenem or colistin resistant Klebsiella pneumoniae bacteremia in the intensive care unit.Sci Rep. 2024 Oct 28;14(1):25805. doi: 10.1038/s41598-024-73786-x. Sci Rep. 2024. PMID: 39468105 Free PMC article.
-
Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.Antimicrob Agents Chemother. 2019 Mar 27;63(4):e01989-18. doi: 10.1128/AAC.01989-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30745385 Free PMC article.
References
-
- Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, et al.. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13:785-96; PMID:23969216; http://dx.doi.org/10.1016/S1473-3099(13)70190-7 - DOI - PMC - PubMed
-
- Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 2012; 18:263-72; PMID:22480775; http://dx.doi.org/10.1016/j.molmed.2012.03.003 - DOI - PubMed
-
- Hirsch EB, Tam VH. Detection and treatment option for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119-25; PMID:20378670; http://dx.doi.org/10.1093/jac/dkq108 - DOI - PubMed
-
- Giacobbe DR, Del Bono V, Marchese A, Viscoli C. Early carbapenem-resistant Klebsiella pneumoniae bacteraemia: should we expand the screening? Clin Microbiol Infect 2014; 20:O1157-O1158; PMID:25366247; http://dx.doi.org/10.1111/1469-0691.12804 - DOI - PubMed
-
- Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60-7; PMID:21653305; http://dx.doi.org/10.1093/cid/cir202 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical